Diagnostic value of serum tumor markers evaluation for adnexal masses

被引:10
作者
Terzic, Milan [1 ,2 ]
Dotlic, Jelena [1 ]
Likic, Ivana [1 ,2 ]
Nikolic, Branka [2 ,3 ]
Brndusic, Natasa [1 ]
Pilic, Igor [1 ]
Bila, Jovan [1 ,2 ]
Maricic, Sanja [4 ]
Arsenovic, Nebojsa [5 ]
机构
[1] Clin Ctr Serbia, Clin Obstet & Gynecol, Belgrade 11000, Serbia
[2] Univ Belgrade, Sch Med, Belgrade 11000, Serbia
[3] Clin Obstet & Gynecol Narodni Front, Belgrade 11000, Serbia
[4] Gen Hlth Ctr Savski Venac, Dept Occupat Hlth, Belgrade 11000, Serbia
[5] Lincoln Cty Hosp, Dept Cellular Pathol, PathLinks Pathol Serv, Lincoln LN2 5QY, England
来源
CENTRAL EUROPEAN JOURNAL OF MEDICINE | 2014年 / 9卷 / 02期
关键词
Tumor markers; Preoperative evaluation; Adnexal masses; OVARIAN-CANCER; ULTRASOUND; CARCINOMA; BIOMARKER; PREDICT; CA-125; HE-4;
D O I
10.2478/s11536-013-0218-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The study aim was to investigate the diagnostic value of preoperative serum tumor markers in patients with adnexal masses. Study included all (358) consecutive patients treated for adnexal tumors at the Clinic of Ob/Gyn, Clinical Center of Serbia in 12 months. Tumor marker levels (Ca 125, CEA, HE 4, Ca 19.9, and Ca 15.3), taken from all women on admission, were compared with postoperative histopathological findings of extracted tumors. Results. Women with malignant tumors had the highest levels of Ca 125, CEA, and HE 4 (p < 0.01). Mucinous adenocarcinoma produced the highest amounts of Ca 19.9 and CEA. Ca 15.3 was the highest in women with endometrioid carcinoma. There were no significant differences in the levels of all examined tumor markers (p > 0.05) between women with benign and borderline tumors. Ca 125, HE 4, and Ca 15.3 can discriminate the malignant from other tumor types well. The highest sensitivity, specificity, positive and negative predictive values (91.04%, 87.6%, 67.9%, 77.2%, respectively) were achieved for the combination of Ca 125 and HE 4. Blood levels of examined tumor markers can be good predictors of the adnexal masses nature. For the most precise evaluation the combination of serum tumor markers should be used.
引用
收藏
页码:210 / 216
页数:7
相关论文
共 27 条
[1]   A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors [J].
Ameye, L. ;
Valentin, L. ;
Testa, A. C. ;
Van Holsbeke, C. ;
Domali, E. ;
Van Huffel, S. ;
Vergote, I. ;
Bourne, T. ;
Timmerman, D. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2009, 33 (01) :92-101
[2]   HE4: a new potential early biomarker for the recurrence of ovarian cancer [J].
Anastasi, Emanuela ;
Marchei, Giulia Giovanna ;
Viggiani, Valentina ;
Gennarini, Giuseppina ;
Frati, Luigi ;
Reale, Maria Gabriella .
TUMOR BIOLOGY, 2010, 31 (02) :113-119
[3]  
[Anonymous], 2011, Obstet Gynecol, V117, P742, DOI 10.1097/AOG.0b013e31821477db
[4]   Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? [J].
Ayhan, Ali ;
Guven, Suleyman ;
Guven, Emine Seda Guvendag ;
Kucukali, Turkan .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2007, 86 (04) :484-490
[5]   Prognostic factors for high-risk early-stage epithelial ovarian cancer - A Gynecologic oncology group study [J].
Chan, John K. ;
Tian, Chunqiao ;
Monk, Bradley J. ;
Herzog, Thomas ;
Kapp, Daniel S. ;
Bell, Jeffrey ;
Young, Robert C. .
CANCER, 2008, 112 (10) :2202-2210
[6]   Triage of ovarian masses [J].
Chia, Yin Nin ;
Marsden, Donald E. ;
Robertson, Greg ;
Hacker, Neville F. .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2008, 48 (03) :322-328
[7]   Combined use of biomarkers for detection of ovarian cancer in high-risk women [J].
Donach, Martin ;
Yu, Yinhua ;
Artioli, Grazia ;
Banna, Giuseppe ;
Feng, Weiwei ;
Bast, Robert C., Jr. ;
Zhang, Zhen ;
Nicoletto, Maria O. .
TUMOR BIOLOGY, 2010, 31 (03) :209-215
[8]   Evaluation of adnexal masses: correlation between clinical, ultrasound and histopathological findings [J].
Dotlic, Jelena ;
Terzic, Milan ;
Likic, Ivana ;
Atanackovic, Jasmina ;
Ladjevic, Nebojsa .
VOJNOSANITETSKI PREGLED, 2011, 68 (10) :861-866
[9]   Phase II biomarker trial of a multimarker diagnostic for ovarian cancer [J].
Edgell, Tracey ;
Martin-Roussety, G. ;
Barker, G. ;
Autelitano, D. J. ;
Allen, D. ;
Grant, P. ;
Rice, G. E. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) :1079-1088
[10]   Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer [J].
Granato, Teresa ;
Midulla, Cecilia ;
Longo, Flavia ;
Colaprisca, Barbara ;
Frati, Luigi ;
Anastasi, Emanuela .
TUMOR BIOLOGY, 2012, 33 (05) :1335-1339